The ODPRN conducted a drug class review on inhaled corticosteroids plus long-acting beta 2-agonists (ICS+LABA) combination products for the management of patients with asthma and chronic obstructive pulmonary disease (COPD), as well as long-acting muscarinic antagonists (LAMAs) for COPD. All three reviews were conducted between November 2013 and April 2015.
Please view the final documents for each review below.
Respiratory Reviews
Reimbursement Option Recommendations |
---|
Final Reimbursement Option Recommendations |
Citizen's Panel |
---|
Respiratory Reviews Citzen's Panel Report |
Final Publications |
---|
Comparative safety and effectiveness of long-acting inhaled agents for treating chronic obstructive pulmonary disease: a systematic review and network meta-analysis |
ICS + LABA for COPD: Final Review Documents
Click to view the complete infographic
Click to view the complete research summary
ICS + LABA for Asthma: Final Review Documents
Click to view the complete infographic
Click to view the complete research summary
Stakeholder Feedback |
---|
Comments from stakeholder on the draft report for ICS+LABAs for asthma |
LAMAs for COPD: Final Review Documents
Click to view the complete infographic
Click to view the complete research summary
Stakeholder Feedback |
---|
Comments from stakeholders on draft Reimbursement Option Recommendations |
Comments from stakeholder on the draft report for LAMAs for COPD |
Any questions? Contact us at info@odprn.ca.